These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

186 related items for PubMed ID: 36755290

  • 1. N-terminal pro-B-type natriuretic peptide levels in normotensive and hypertensive dogs with myxomatous mitral valve disease stage B.
    Jang IS, Yoon WK, Choi EW.
    Ir Vet J; 2023 Feb 08; 76(1):3. PubMed ID: 36755290
    [Abstract] [Full Text] [Related]

  • 2. Comparison of N-terminal pro-atrial natriuretic peptide and three cardiac biomarkers for discriminatory ability of clinical stage in dogs with myxomatous mitral valve disease.
    Ogawa M, Hori Y, Kanno N, Iwasa N, Toyofuku T, Isayama N, Yoshikawa A, Akabane R, Sakatani A, Miyakawa H, Hsu HH, Miyagawa Y, Takemura N.
    J Vet Med Sci; 2021 Apr 24; 83(4):705-715. PubMed ID: 33551383
    [Abstract] [Full Text] [Related]

  • 3. How accurate are NT-proBNP, ANP, and cTnI levels in diagnosing dogs with myxomatous mitral valve disease?
    Chanmongkolpanit K, Riengvirodkij N, Channgam P, Kaenchan P, Buayam W, Janhirun Y, Phonarknguen R, Tansakul M, Sakcamduang W.
    Open Vet J; 2024 Jun 24; 14(6):1426-1441. PubMed ID: 39055758
    [Abstract] [Full Text] [Related]

  • 4. The predictive value of clinical, radiographic, echocardiographic variables and cardiac biomarkers for assessing risk of the onset of heart failure or cardiac death in dogs with preclinical myxomatous mitral valve disease enrolled in the DELAY study.
    Borgarelli M, Ferasin L, Lamb K, Chiavegato D, Bussadori C, D'Agnolo G, Migliorini F, Poggi M, Santilli RA, Guillot E, Garelli-Paar C, Toschi Corneliani R, Farina F, Zani A, Dirven M, Smets P, Guglielmini C, Oliveira P, Di Marcello M, Porciello F, Crosara S, Ciaramella P, Piantedosi D, Smith S, Vannini S, Dall'Aglio E, Savarino P, Quintavalla C, Patteson M, Silva J, Locatelli C, Baron Toaldo M.
    J Vet Cardiol; 2021 Aug 24; 36():77-88. PubMed ID: 34118562
    [Abstract] [Full Text] [Related]

  • 5. Diagnostic value of atrial natriuretic peptide (ANP), B-type natriuretic peptide (BNP) and their correlation with lipoproteins in dogs with myxomatous mitral valve disease.
    Khaki Z, Nooshirvani P, Shirani D, Masoudifard M.
    BMC Vet Res; 2022 Dec 23; 18(1):448. PubMed ID: 36564735
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Plasma humanin as a prognostic biomarker for canine myxomatous mitral valve disease: a comparison with plasma NT-roBNP.
    Mangkhang K, Punyapornwithaya V, Tankaew P, Pongkan W, Chattipakorn N, Boonyapakorn C.
    Pol J Vet Sci; 2018 Dec 23; 21(4):673-680. PubMed ID: 30605282
    [Abstract] [Full Text] [Related]

  • 8. The diagnostic relevance of NT-proBNP and proANP 31-67 measurements in staging of myxomatous mitral valve disease in dogs.
    Wolf J, Gerlach N, Weber K, Klima A, Wess G.
    Vet Clin Pathol; 2013 Jun 23; 42(2):196-206. PubMed ID: 23614733
    [Abstract] [Full Text] [Related]

  • 9. Can cartilage intermediate layer protein 1 (CILP1) use as a novel biomarker for canine myxomatous mitral valve degeneration levels or not?
    Kim HJ, Kim J, Kim S, Kim HJ.
    BMC Vet Res; 2023 Mar 07; 19(1):59. PubMed ID: 36882760
    [Abstract] [Full Text] [Related]

  • 10. DELay of Appearance of sYmptoms of Canine Degenerative Mitral Valve Disease Treated with Spironolactone and Benazepril: the DELAY Study.
    Borgarelli M, Ferasin L, Lamb K, Bussadori C, Chiavegato D, D'Agnolo G, Migliorini F, Poggi M, Santilli RA, Guillot E, Garelli-Paar C, Toschi Corneliani R, Farina F, Zani A, Dirven M, Smets P, Guglielmini C, Oliveira P, Di Marcello M, Porciello F, Crosara S, Ciaramella P, Piantedosi D, Smith S, Vannini S, Dall'Aglio E, Savarino P, Quintavalla C, Patteson M, Silva J, Locatelli C, Baron Toaldo M.
    J Vet Cardiol; 2020 Feb 07; 27():34-53. PubMed ID: 32032923
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Effect of prespecified therapy escalation on plasma NT-proBNP concentrations in dogs with stable congestive heart failure due to myxomatous mitral valve disease.
    Hezzell MJ, Block CL, Laughlin DS, Oyama MA.
    J Vet Intern Med; 2018 Sep 07; 32(5):1509-1516. PubMed ID: 30216549
    [Abstract] [Full Text] [Related]

  • 13. Short-Term Effects of Sacubitril/valsartan on Echocardiographic Parameters in Dogs With Symptomatic Myxomatous Mitral Valve Disease.
    Saengklub N, Pirintr P, Nampimoon T, Kijtawornrat A, Chaiyabutr N.
    Front Vet Sci; 2021 Sep 07; 8():700230. PubMed ID: 34386539
    [Abstract] [Full Text] [Related]

  • 14. Lowered N-terminal pro-B-type natriuretic peptide levels in response to treatment predict survival in dogs with symptomatic mitral valve disease.
    Wolf J, Gerlach N, Weber K, Klima A, Wess G.
    J Vet Cardiol; 2012 Sep 07; 14(3):399-408. PubMed ID: 22858663
    [Abstract] [Full Text] [Related]

  • 15. N-terminal pro-B-type natriuretic peptide and its relationship with cardiac function in adults with congenital heart disease.
    Eindhoven JA, van den Bosch AE, Ruys TP, Opić P, Cuypers JA, McGhie JS, Witsenburg M, Boersma E, Roos-Hesselink JW.
    J Am Coll Cardiol; 2013 Sep 24; 62(13):1203-12. PubMed ID: 23916937
    [Abstract] [Full Text] [Related]

  • 16. Association of Paraoxonase-1 and NT-proBNP with Clinical, Clinico-Pathologic and Echocardiographic Variables in Dogs with Mitral Valve Disease.
    Rammal D, Koutinas CK, Athanasiou LV, Tangalidi M, Rubio CP, Cerón JJ, Tamvakis A, Patsikas MN, Polizopoulou ZS.
    Vet Sci; 2023 Jan 01; 10(1):. PubMed ID: 36669034
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Diagnostic Value of Selected Echocardiographic Variables to Identify Pulmonary Hypertension in Dogs with Myxomatous Mitral Valve Disease.
    Tidholm A, Höglund K, Häggström J, Ljungvall I.
    J Vet Intern Med; 2015 Jan 01; 29(6):1510-7. PubMed ID: 26365438
    [Abstract] [Full Text] [Related]

  • 20. Effect of standard-dose and high-dose pimobendan on select indices of renal and cardiac function in dogs with American College of Veterinary Internal Medicine stage B2 myxomatous mitral valve disease.
    Kaplan JL, Visser LC, Gunther-Harrington CT, Ontiveros ES, Wittenburg LA, Palm CA, Stern JA.
    J Vet Intern Med; 2022 Nov 01; 36(6):1892-1899. PubMed ID: 36098206
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.